Experimental radioimmunotherapy with super(186)Re-MAG3-A7 anti-colorectal cancer monoclonal antibody: Comparison with super(131)I-counterpart

A murine IgG1 against aMr 45 kD tumor-associated glycoprotein in human colorectal cancer, A7, was radiolabeled with super(186)Re by a chelating method with a mercaptoacetyltriglycine (MAG3). Its specific activity was 119 MBq/mg, which would be high enough for a therapeutic purpose, and its immunorea...

Full description

Saved in:
Bibliographic Details
Published inAnnals of nuclear medicine Vol. 15; no. 3; pp. 199 - 202
Main Authors Kinuya, Seigo, Yokoyama, Kunihiko, Kobayashi, Katsutoshi, Motoishi, Shoji, Onoma, Katsuyuki, Watanabe, Naoto, Shuke, Noriyuki, Bunko, Hisashi, Michigishi, Takatoshi, Tonami, Norihisa
Format Journal Article
LanguageEnglish
Published 01.06.2001
Online AccessGet full text

Cover

More Information
Summary:A murine IgG1 against aMr 45 kD tumor-associated glycoprotein in human colorectal cancer, A7, was radiolabeled with super(186)Re by a chelating method with a mercaptoacetyltriglycine (MAG3). Its specific activity was 119 MBq/mg, which would be high enough for a therapeutic purpose, and its immunoreactivity was preserved well as was super(131)I-A7 labeled by the chloramine-T method. Growth of human colon cancer xenografts, 9.14c0.44 mm in diameter, in nude mice was significantly suppressed by an intravenous dose of 4.48 MBq of super(186)Re-A7. The therapeutic outcome with super(186)Re-A7 was better than that with 4.63 MBq of super(131)I-A7. Toxicity of treatments assessed by body weight change was similar with both conjugates. These results are likely caused by the tumor size and more favorable physical properties of super(186)Re than those of super(131)I.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
content type line 23
ObjectType-Feature-2
ISSN:0914-7187
1864-6433
DOI:10.1007/BF02987831